Journal
JOURNAL OF NEUROLOGY
Volume 265, Issue 3, Pages 717-727Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-017-8652-3
Keywords
IDH; ATRX; TERT; EGFR; BRAF; Histone; Mutation; Astrocytoma; Oligodendroglioma; Glioblastoma; Ependymoma; BRAF inhibitor; Tumour heterogeneity; MGMT; Temozolomide
Categories
Funding
- Cancer Research UK [C416/A23615]
- National Institute for Health Research Biomedical Research Centre's funding scheme
- Brain Tumour Charity [8/128]
- Brain Tumour Research UK
- Cancer Research UK [23615] Funding Source: researchfish
- The Brain Tumour Charity [8/128] Funding Source: researchfish
Ask authors/readers for more resources
The emerging understanding of molecular changes in a wide range of brain tumours has led to a significant shift in how these tumours are diagnosed, managed and treated. This article will provide a hands-on overview of the relevant biomarkers and their association with newly defined biological tumour entities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
